Temozolomide (Kizfizo)
Treatment of adults with glioblastoma multiforme and children with malignant glioma
Second interim analysis in 751 adults with 1p/19q non-co-deleted anaplastic glioma: concurrent temozolomide with radiotherapy was futile (median OS 66·9 vs 60·4 months; HR 0·97), while adjuvant temozolomide improved OS (82·3 vs 46·9 months; HR 0·64). RCT · phase 3 · n = 751 · Lancet Oncol · 2021
In 129 of 141 randomised patients with newly diagnosed MGMT-methylated glioblastoma, lomustine-temozolomide plus radiotherapy vs temozolomide chemoradiotherapy: median OS 48·1 vs 31·4 months (HR 0·60, 95% CI 0·35–1·03; p=0·0492). Grade ≥3 events 59% vs 51%. RCT · phase 3 · n = 141 · Lancet · 2019